Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vicore Pharma Holding AB ( (SE:VICO) ) has issued an announcement.
Vicore Pharma announced that its senior leadership team will present and hold one-on-one meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026, with the session also accessible via webcast. Participation in this high-profile investor event underscores the company’s efforts to raise its visibility within the global healthcare investment community and could support partnering and financing opportunities as it advances its ATRAG-based pipeline and lead IPF program, buloxibutid.
The most recent analyst rating on (SE:VICO) stock is a Hold with a SEK12.00 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of angiotensin II type 2 receptor agonists (ATRAGs) with disease-modifying potential in respiratory and fibrotic conditions, notably idiopathic pulmonary fibrosis (IPF). Its lead candidate, buloxibutid, is a first-in-class oral small molecule that has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and is currently being evaluated in a global 52-week Phase 2b ASPIRE trial in IPF. The company is listed on Nasdaq Stockholm under the ticker VICO.
Average Trading Volume: 521,047
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.97B
See more insights into VICO stock on TipRanks’ Stock Analysis page.